Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Receivables (2016 - 2025)

Heron Therapeutics' Receivables history spans 11 years, with the latest figure at $89.7 million for Q4 2025.

  • For Q4 2025, Receivables rose 13.4% year-over-year to $89.7 million; the TTM value through Dec 2025 reached $89.7 million, up 13.4%, while the annual FY2025 figure was $89.7 million, 13.4% up from the prior year.
  • Receivables reached $89.7 million in Q4 2025 per HRTX's latest filing, up from $81.0 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $89.7 million in Q4 2025 to a low of $35.6 million in Q4 2021.
  • Average Receivables over 5 years is $60.4 million, with a median of $62.0 million recorded in 2023.
  • Peak YoY movement for Receivables: fell 15.6% in 2021, then surged 90.29% in 2023.
  • A 5-year view of Receivables shows it stood at $35.6 million in 2021, then skyrocketed by 63.6% to $58.2 million in 2022, then rose by 3.28% to $60.2 million in 2023, then soared by 31.56% to $79.1 million in 2024, then increased by 13.4% to $89.7 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Receivables are $89.7 million (Q4 2025), $81.0 million (Q3 2025), and $79.9 million (Q2 2025).